Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan N Chi

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Nature Communications|July 11, 2024
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
Nature Communications|August 22, 2024
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
Neuro-Oncology|January 21, 2017
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumorsShakti H Ramkissoon, Pratiti Bandopadhayay, Jaeho Hwang, et al.
Nature Cancer|July 5, 2022
Structural variants shape driver combinations and outcomes in pediatric high-grade gliomaFrank P B Dubois, Ofer Shapira, Noah F Greenwald, et al.
Nature Cancer|May 26, 2025
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactionsAlexander Beck, Lisa Gabler-Pamer, Gustavo Alencastro Veiga Cruzeiro, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Neuro-Oncology|May 10, 2018
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine gliomaNalin Gupta, Liliana C Goumnerova, Peter Manley, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Nature Communications|July 11, 2024
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
Nature Communications|August 22, 2024
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancerSuzanne J Forrest, Hersh Gupta, Abigail Ward, et al.
Neuro-Oncology|January 21, 2017
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumorsShakti H Ramkissoon, Pratiti Bandopadhayay, Jaeho Hwang, et al.
Nature Cancer|July 5, 2022
Structural variants shape driver combinations and outcomes in pediatric high-grade gliomaFrank P B Dubois, Ofer Shapira, Noah F Greenwald, et al.
Nature Cancer|May 26, 2025
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactionsAlexander Beck, Lisa Gabler-Pamer, Gustavo Alencastro Veiga Cruzeiro, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Neuro-Oncology|May 10, 2018
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine gliomaNalin Gupta, Liliana C Goumnerova, Peter Manley, et al.
Pageof 9